Exact Sciences (EXAS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $20.03B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Kevin T. Conroy |
| IPO Date | 2001-02-01 | CAGR | — |
| Employees | 6,900 | Website | www.exactsciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $20.84B | P/E | -95.37 | Forward P/E | — | PEG | — |
| P/S | 6.17 | P/B | 8.29 | P/CF | 40.5 | P/FCF | 56.13 |
| Sales | $3.25B | Sales 1Y | 17.69% | Sales 3Y | 55.78% | Sales 5Y | 117.72% |
| EPS | $-1.1 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 3.25% | EPS QoQ | 350% | Sales QoQ Avg | 5.49% | EPS QoQ Avg | 412.51% |
| Gross Margin | 69.69% | Operating Margin | -6.17% | Profit Margin | -6.4% | ROCE | -3.84% |
| ROA | -4% | ROE | -9% | Altman Z Score | 2.96 | Piotroski Score | 5 |
| Current Ratio | 2.23 | Quick Ratio | 1.97 | Cash Ratio | 1.49 | Op. CF Ratio | 0.24 |
| Debt/Equity | 1.05 | Debt/Assets | 0.43 | Lt Debt/Equity | 1.04 | Lt Debt/Cap. | 0.49 |
| Intrst Cov. | -5.47 | Inventory Turnover | 5.92 | Asset Turnover | 0.55 | Receivables Turnover | 10.87 |
| Enterprise Value | $20.84B | P/E Ratio | -95.37 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 6.17 | P/B Ratio | 8.29 |
| P/CF Ratio | 40.5 | P/FCF Ratio | 56.13 |
| EPS | $-1.1 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 17.69% | Gross Margin | 0.7% |
| Operating Margin | -0.06% | Profit Margin | -0.06% |
| ROE | -0.09% | ROA | -0.04% |
| ROCE | -0.04% | Current Ratio | 2.23 |
| Quick Ratio | 1.97 | Cash Ratio | 1.49 |
| Debt/Equity | 1.05 | Interest Coverage | -5.47 |
| Altman Z Score | 2.96 | Piotroski Score | 5 |
Exact Sciences (EXAS) valuation & financials
Exact Sciences (EXAS) has a market capitalization of $20.03B and trades at a price-to-earnings ratio of -95.4. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Exact Sciences's revenue grew +17.7% over the last year.
Exact Sciences's next earnings report is scheduled for May 7, 2026 after market close; analysts estimate EPS of $0.13. Check the earnings calendar to see all companies reporting this week.
Exact Sciences (EXAS) — frequently asked questions
When does Exact Sciences (EXAS) report earnings next?
Exact Sciences is expected to report earnings on May 7, 2026 after market close. Analysts estimate EPS of $0.13.
What is Exact Sciences's market cap?
Exact Sciences (EXAS) has a market capitalization of $20.03B.
What is EXAS's P/E ratio?
Exact Sciences trades at a price-to-earnings ratio of -95.4, with trailing twelve-month EPS of $-1.10.
How fast is Exact Sciences growing?
Exact Sciences's revenue grew +17.7% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)